FDA 2026 Human Factors Guidance: Category 1, 2, 3 Submission Strategy[GeXPs26-0720EN]

On May 28, 2026, the U.S. Food and Drug Administration (FDA) issued its final guidance, Content of Human Factors Information in Medical Device Marketing Submissions. The guidance explains how manufacturers should determine the level of human factors information to include in 510(k), De Novo, PMA, and HDE submissions.

The central question is not whether every device needs a new human factors validation test. It is whether the proposed device, its users, its use environment, or its user interface introduces or affects critical tasks—and whether existing evidence is sufficient to support the submission.

For medical device manufacturers, regulatory affairs teams, design engineers, and brand owners, the practical task is to determine the correct Human Factors Submission Category, document the reasoning, and submit evidence that is proportionate to the actual use-related risk.

Executive Summary

The framework is based on device modifications, critical tasks, the use-related risk analysis, user-interface history, complexity, and existing risk controls—not simply on device class.
FDA states that submissions received before August 1, 2026 generally are not expected to include all newly recommended information because industry and FDA may need at least 60 days to operationalize the guidance.
A new human factors validation test is not automatically required. In some cases, a well-supported rationale and objective evidence may justify relying on existing information.
When the appropriate category or evidence package is uncertain, manufacturers should consider seeking FDA feedback through the Pre-Submission process.

What Changed: A Risk-Based Submission Framework

The final guidance establishes a risk-based method for determining how much human factors information should be included in a medical device marketing submission. FDA calls this the Human Factors Submission Category.

The framework applies to both new devices and modifications to devices that have already received FDA marketing authorization. It considers:

whether the submission concerns a new device or a modification;
whether the user interface, intended users, intended use, use environment, training, or labeling has changed;
whether the device has critical tasks;
whether a modification introduces new critical tasks or affects existing critical tasks; and
whether human factors validation test data should be submitted.

A critical task is a user task that, if performed incorrectly or not performed at all, could cause serious harm. A device’s user interface is broader than its software screen. It can include physical controls, displays, alarms, connectors, packaging, labeling, training materials, and the logic of operation.

Five Actions for Medical Device Manufacturers

Define the intended users and use environments.
Identify who will use the device and under what conditions. A device used by trained clinicians in a controlled hospital setting may present different use-related risks from the same device used by patients or caregivers at home.
Build or update the Use-Related Risk Analysis.
The Use-Related Risk Analysis (URRA) should identify user tasks, foreseeable use errors, hazardous situations, potential harm, risk-control measures, and critical tasks.
Compare the proposed device with relevant existing evidence.
Review prior human factors evaluations, known use problems, complaint data, postmarket information, labeling, training, task analyses, and comparable legally marketed devices.
Decide whether a new validation test should be submitted.
Consider user-interface history, complexity, the adequacy of existing risk controls, intended users, use environments, and the clinical consequences of use error.
Prepare the category-specific submission package.
Document the decision path, the selected category, the evidence relied upon, and the rationale for submitting—or not submitting—new human factors validation test data.

Understanding the Three Human Factors Submission Categories

Category	How It Is Reached	Core Submission Content
Category 1	For a modified device, there is no change to the user interface, intended users, intended use, use environment, training, or labeling that affects the human factors assessment.	A conclusion and high-level summary explaining why the modification does not affect the device’s human factors considerations, including any prior HFE/UE information being leveraged.
Category 2	Either no critical tasks are identified for a new device, no new or impacted critical tasks are identified for a modified device, or a supported rationale can justify not submitting new human factors validation test data.	A clear rationale supported by the URRA, comparative analysis, existing evidence, and objective evidence that applicable risk controls remain effective.
Category 3	Human factors validation test data should be submitted based on the decision framework, including situations involving significant differences, complex interfaces, known use-error concerns, new safety signals, or increased severity of harm.	A comprehensive HFE/UE report that includes human factors validation testing and the supporting analyses described in the guidance.

Important: These categories are not the same as FDA device Classes I, II, and III. A Category 1 submission is not automatically a low-risk device, and a Category 3 submission is not automatically a high-risk device. The categories describe the level of human factors information recommended for the marketing submission.

Two Practical Scenarios

Scenario 1: Major Change to the User Interface

A manufacturer replaces the physical controls of an infusion device with a touchscreen workflow. The intended use may remain the same, but the sequence of tasks, visual hierarchy, alarm presentation, and programming steps change. Because the modification can affect critical tasks and the device type has a history of use-error concerns, new human factors validation test data may be needed.

Scenario 2: Manufacturing Transfer Without a Meaningful Human Factors Change

A manufacturer transfers production to a contract manufacturer but keeps the final finished device, controls, labeling, training, packaging interaction, and operating logic unchanged. The company should still document the comparison and assess the final finished device through its URRA. If the evidence demonstrates that no relevant human factors change occurred, the submission may fall within Category 1, depending on the facts of the modification and the marketing submission.

By contrast, a manufacturing transfer that changes a switch, connector, package-opening method, labeling, or training material may affect user interaction and should not be treated as automatically insignificant.

When Existing Evidence May Support the Submission

FDA allows manufacturers to consider a rationale in place of new human factors validation testing when critical tasks are affected but existing risk-control measures remain effective. The rationale should be supported by objective evidence.

Useful evidence may include:

prior HFE/UE evaluations for the same or a sufficiently similar user interface;
a comparative URRA or task analysis;
known-use-problem analyses;
complaint, adverse-event, recall, and postmarket data;
labeling, training, and user-interface comparisons; and
evidence showing that existing risk controls remain effective for the intended users, uses, and environments.

Existing evidence does not create an automatic exemption from testing. The manufacturer must explain why the evidence is relevant and sufficient for the specific device and submission.

When New Validation Data Are More Likely to Be Needed

Human factors validation test data are more likely to be needed when:

the device has a complex user interface;
the device type has known use-error problems;
there are significant differences from similar legally marketed devices that affect use;
the intended users, indications, or use environment change;
complaints, adverse events, recalls, or problem reports identify a use-error safety signal; or
the severity of possible harm from use error has increased.

August 2026 Readiness Checklist

□ Identify submissions expected to be filed on or after August 1, 2026.
□ Confirm whether the device is new or modified.
□ Document changes to the user interface, intended users, intended use, use environment, training, and labeling.
□ Update the URRA for the final finished device.
□ Identify all critical tasks and any new or affected critical tasks.
□ Inventory prior HFE/UE evidence and relevant postmarket information.
□ Prepare the rationale supporting the selected HF Submission Category.
□ Confirm that the electronic submission template and internal procedures reflect the current FDA requirements and recommendations at the time of filing.

Use Pre-Submission Feedback When the Decision Is Unclear

FDA recommends that submitters seek feedback through a Pre-Submission when they are uncertain whether a rationale is appropriate in place of human factors validation testing. Early feedback can reduce the risk of building the wrong evidence package or discovering a major documentation gap late in the review process.

Conclusion: Right-Size the Evidence

The 2026 final guidance does not require every manufacturer to repeat human factors validation testing. It requires a disciplined explanation of the device, its users, its use environment, its critical tasks, its changes, and the evidence supporting the submission.

The best starting point is not “How quickly can we book a new study?” It is:

What has changed, which critical tasks are affected, and what evidence demonstrates that the remaining use-related risks are adequately controlled?

Frequently Asked Questions

Is the guidance legally binding?

No. FDA guidance documents generally describe the agency’s current thinking and contain nonbinding recommendations unless specific statutory or regulatory requirements are cited.

Does historical market experience automatically eliminate the need for new testing?

No. Historical evidence can be valuable, but the manufacturer must explain why it is relevant to the proposed device, users, uses, use environments, and critical tasks.

What does “user interface” include?

It can include packaging, labeling, training materials, physical controls, display elements, alarms, connectors, and the operating logic through which a user interacts with the device.

Does a contract manufacturing transfer automatically trigger new human factors validation testing?

No. The effect depends on whether the final finished device or its associated labeling, training, packaging interaction, controls, or operating logic changes in a way that affects the human factors assessment or critical tasks.

What is the difference between HF Submission Category and device class?

Device class addresses the device’s regulatory classification. HF Submission Category addresses the recommended level of human factors information in a particular marketing submission. They are separate concepts.

Disclaimer: This article is provided for general informational and educational purposes and does not constitute legal, regulatory, quality-system, or product-specific consulting. Manufacturers should review the final FDA guidance, applicable device-specific requirements, and current submission instructions, and should obtain qualified advice for individual products.

Official FDA Sources

FDA guidance issued: May 28, 2026
Article reviewed: July 20, 2026

Search This Blog

eXGateAI Global Trade Intelligence